Introduction
The Inflation Reduction Act's Medicare drug price negotiation provisions represent the most significant change to US pharmaceutical pricing policy in decades. For healthcare bankers, the IRA is not just a political risk factor; it is a structural shift that changes how pharma companies are valued, how pipeline assets are prioritized, and which M&A targets are most attractive.
This article walks through the negotiation mechanics, the pill penalty between small molecules and biologics, what the first negotiation cycles actually delivered, and how to build the IRA into a product-level revenue model without overstating the hit.
How IRA Negotiation Works
A drug becomes eligible for selection when it has been approved for at least 7 years (small molecules) or 11 years (biologics), has no generic or biosimilar competition, and ranks among the highest-spend drugs in Medicare. Selection does not cut the price immediately. CMS announces its selections by February 1, negotiates with the manufacturer during that year, publishes the agreed price by November 30, and the price takes effect on January 1 of the second year after selection (a drug selected in early 2026 gets its new price in January 2028). In practice, the negotiated price bites roughly 2 years after selection, around year 9 for a small molecule and year 13 for a biologic.
The program started with Part D (pharmacy-dispensed) drugs and adds Part B (physician-administered) drugs from 2028. The number of selected drugs rises from 10 for 2026 to 15 for 2027 and 2028, then up to 20 per year from 2029.
- Maximum Fair Price (MFP)
The price that CMS and a manufacturer agree for a selected drug under the IRA's Medicare negotiation program. The MFP cannot exceed a statutory ceiling set as a percentage of the drug's non-federal average manufacturer price (non-FAMP): 75% for drugs approved fewer than 12 years, 65% for drugs 12-16 years on market, and 40% for drugs 16+ years on market. Because a drug cannot be selected before year 7 (small molecules) or year 11 (biologics), the earliest MFPs apply around year 9 or year 13.
CMS holds most of the negotiating leverage. A manufacturer that refuses to agree faces an excise tax on its Medicare sales of the drug that starts at roughly 186% of the sales price and escalates to 1,900%, or it must pull all of its drugs out of Medicare and Medicaid. Neither is a realistic option, so selected manufacturers have chosen to negotiate rather than pay. The real negotiation is over how far below the ceiling the final price lands.
The Pill Penalty: Small Molecules vs. Biologics
The most strategically significant provision of the IRA is the 4-year timing differential between small molecules and biologics.
- Pill Penalty
The industry term for the IRA's shorter negotiation runway for small molecule drugs, which can be selected 7 years after approval versus 11 years for biologics. The gap gives biologics roughly 4 extra years at full Medicare pricing and is the main reason the IRA tilts R&D and M&A toward large molecules.
Laid side by side, the three regulatory treatments look like this:
| Drug Type | Eligible for Selection | MFP Takes Effect | Strategic Implication |
|---|---|---|---|
| Small molecule | 7 years post-approval | ~Year 9 | Shorter full-price window before the cap |
| Biologic | 11 years post-approval | ~Year 13 | Cap often arrives near biosimilar entry |
| Orphan-only drug | Excluded | Not applicable | Clock starts only at first non-orphan approval |
The table understates one nuance: the cap only matters while a drug still has exclusivity. Many small molecules face generic entry somewhere around 12 to 14 years after approval under the Hatch-Waxman framework, so the negotiated price governs a window of a few years before loss of exclusivity. A biologic's MFP at year 13 arrives after its 12-year data exclusivity has expired, so biosimilar competition, not Medicare, often sets its late-life price. Once a generic or biosimilar is marketed, the drug drops out of the program.
What the First Negotiation Cycles Show
Realized net cuts give modelers a better anchor than the statutory ceilings. CMS estimated that the first ten prices would have produced 22% lower net spending in aggregate, about $6 billion, had they applied in 2023, according to the CMS fact sheet on the first negotiated prices. The second cycle went deeper: CMS reported 44% net savings on 15 drugs, or about $12 billion against prior negotiated spending.
| Cycle | Drugs | Prices Effective | Notable Features |
|---|---|---|---|
| First | 10 Part D | January 2026 | Eliquis, Jardiance, Xarelto, Januvia, Stelara; 22% aggregate net cut |
| Second | 15 Part D | January 2027 | Ozempic, Wegovy and Rybelsus included; 44% aggregate net cut |
| Third | 15 Part B and D | January 2028 | First Part B drugs plus the first renegotiation (Tradjenta) |
The third-cycle list, which includes Part B products such as Orencia, Entyvio and Xolair, is summarized in KFF's key facts on Medicare negotiation; its negotiated prices are due by the end of 2026.
Strategic Responses
The pharma industry is adapting to the IRA through several portfolio and pricing shifts:
Biologics preference. The pill penalty accelerates the industry's existing trend toward biologic development. Companies are prioritizing antibodies, ADCs, cell therapies and gene therapies over small molecules in R&D portfolio decisions, a shift Congress has been asked to reverse through the EPIC Act, which would move small molecules to the 11-year biologic timeline.
Orphan drug focus. The original IRA excluded only drugs with a single orphan indication. The 2025 reconciliation law (covered in our One Big Beautiful Bill policy article) broadened the orphan exclusion to drugs designated for one or more rare diseases, and, as Sidley's summary of the amendment explains, the negotiation clock now starts only when a non-orphan indication is approved. That makes rare disease programs more valuable and rewards orphan-first launch sequencing; KFF judges that the change likely delayed the selection of Keytruda and Opdivo.
Launch pricing and inflation rebates. The IRA also requires manufacturers to pay Medicare rebates when prices rise faster than inflation. Combined with a capped tail, that pushes companies toward higher launch prices and away from the traditional strategy of steady annual price increases.
Accelerated indication expansion. Companies pursue additional indications earlier to capture more value during the full-price window, since a new label does not reset the negotiation clock: an indication added late in the product's life earns much of its Medicare revenue at the negotiated price.
Modeling the IRA in Pharma Valuation
When building pharma valuation models post-IRA, healthcare bankers adjust revenue projections for exposed products:
- 1.Identify exposed products based on approval date, drug type (small molecule vs. biologic), orphan status and Medicare spend rank
- 2.Set the MFP effective year, not just the selection year: roughly approval plus 9 years for small molecules and plus 13 for biologics
- 3.Apply the net price cut to Medicare volume only, using realized cycle results rather than the statutory ceiling or list-price discounts
- 4.Stop the IRA adjustment at loss of exclusivity, since generic or biosimilar entry removes the drug from the program
- 5.Reflect the compressed tail in terminal value for companies whose cash flows depend on aging small molecule franchises
The broader deal implications, including how buyers screen targets, are covered in the IRA and healthcare dealmaking.
In interviews, the IRA usually comes up as a current-events question, and the strongest answers show you understand both the timeline and the valuation mechanics.
The next two articles cover specific pharma sub-segments: generic pharma and specialty pharma, each with distinct business models and valuation dynamics.
